Halt Medical has been approved to market the Tulip Radiofrequency Volumetric Thermal Ablation (RFVTA) probe in Canada.
The Halt system has been cleared by the US Food and Drug Administration for general use and is currently being studied in the US and Latin America for relief of symptoms caused by uterine fibroids.
Halt Medical is preparing to commercialise the Halt Fibroid System in markets outside the US where it has already been approved for general surgical and fibroid indications.
Halt Medical president and COO Russ DeLonzor said that the license just received from Health Canada brings an important step closer to the goal of making their uterine sparing procedure available to the millions of women in North America who suffer with uterine fibroids.
“The approvals we’ve now received from Canada and the European Union for general use and for treating uterine fibroids, plus our recent clearance by the FDA to market our products for general surgical use (not specifically indicated for fibroids) in the United States has us well positioned to bring our solutions to most of the major global markets in the near future,” DeLonzor said.